Researchers have developed a bioadhesive based on mussel adhesive protein to help wounds heal with minimal scarring. The adhesive assists skin transplantation in healing the skin without the use of sutures.
Psoriasis patients value skin clearance, symptom control as most important treatment outcomes
Patients with psoriasis value skin clearance and symptom control as the most important treatment outcomes, according to a new study.
Thirdhand smoke exposure can cause skin damage
According to a new study concentrations of nicotine that settle on surfaces, also called thirdhand smoke (THS), as well as electronic cigarette spills can damage the skin.
Study suggests prevalence of keratosis pilaris is low in AD patients
According to a new study, the prevalence of keratosis pilaris (KP) is low in patients with atopic dermatitis (AD).
New study shows tildrakizumab may be effective for difficult-to-treat areas in psoriasis
According to a new study, tildrakizumab treatment for psoriasis showed a significant improvement when used for difficult-to-treat areas such as the scalp, nail, palms and genitals.
Depressive symptoms linked to AD severity
According to a new study, depressive symptoms are closely linked to atopic dermatitis (AD) severity and can fluctuate alongside AD severity.
Dupilumab study shows safety and efficacy for up to four years in AD patients
According to a new study, dupilumab shows safety and efficacy for up to four years in treatment of moderate-to-severe atopic dermatitis (AD) in adults.
New study suggests psoriasis patients are at increased risk of developing alopecia areata
According to a new study, patients with psoriasis are at an increased risk of developing alopecia areata.
New study shows microbotox an effective treatment for acne and rosacea
Microbotox, a specific dilution of onabotulinum toxin A, is effective in treating mild-to-moderate acne vulgaris and erythematotelangiectatic rosacea, according to a new study.
Dupilumab and adjuvant tacrolimus improves severity of AD, new study shows
According to a new study, patients with atopic dermatitis (AD) are more likely to achieve mild disease severity when treated with dupilumab and adjuvant tacrolimus as opposed to dupilumab alone.
HealthMinute.TV 